Rosen, Neal

Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.

Ercan, D., Xu, C., Yanagita, M., Monast, C. S., Pratilas, C. A., Montero, J., Butaney, M., Shimamura, T., Sholl, L., Ivanova, E. V., et al. (2012) · Cancer Discovery

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 294

Pilot Trial of Combined BRAF and EGFR Inhibition in BRAF -Mutant Metastatic Colorectal Cancer Patients

Yaeger, R., Cercek, A., O'Reilly, E. M., Reidy, D. L., Kemeny, N., Wolinsky, T., Capanu, M., Gollub, M. J., Rosen, N., Berger, M. F., et al. (2015) · Clinical Cancer Research

Colorectal Cancer Treatments and StudiesMelanoma and MAPK Pathways

Cited by 276

Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)

Dry, J. R., Pavey, S., Pratilas, C. A., Harbron, C., Runswick, S., Hodgson, D., Chresta, C., McCormack, R., Byrne, N., Cockerill, M., et al. (2010) · Cancer Research

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 262

RAF inhibitor PLX8394 selectively disrupts BRAF dimers and RAS-independent BRAF-mutant-driven signaling

Yao, Z., Gao, Y., Su, W., Yaeger, R., Tao, J., Na, N., Zhang, Y., Zhang, C., Rymar, A., Tao, A., et al. (2019) · Nature Medicine

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 195

RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer

Yaeger, R., Cowell, E., Chou, J. F., Gewirtz, A. N., Borsu, L., Vakiani, E., Solit, D. B., Rosen, N., Capanu, M., Ladanyi, M., et al. (2015) · Cancer

Colorectal Cancer Treatments and StudiesColorectal Cancer Surgical Treatments

Cited by 187

Enhanced Inhibition of ERK Signaling by a Novel Allosteric MEK Inhibitor, CH5126766, That Suppresses Feedback Reactivation of RAF Activity

Ishii, N., Harada, N., Joseph, E. W., Ohara, K., Miura, T., Sakamoto, H., Matsuda, Y., Tomii, Y., Tachibana-Kondo, Y., Iikura, H., et al. (2013) · Cancer Research

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 179

An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer

Xue, Y., Martelotto, L., Baslan, T., Vides, A., Solomon, M., Mai, T. T., Chaudhary, N., Riely, G. J., Li, B. T., Scott, K., et al. (2017) · Nature Medicine

Melanoma and MAPK PathwaysCancer Genomics and Diagnostics

Cited by 174

PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS Signaling

Halilovic, E., She, Q.-B., Ye, Q., Pagliarini, R., Sellers, W. R., Solit, D. B., & Rosen, N. (2010) · Cancer Research

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 168

Mutant-selective degradation by BRAF-targeting PROTACs

Alabi, S., Jaime-Figueroa, S., Yao, Z., Gao, Y., Hines, J., Samarasinghe, K. T. G., Vogt, L., Rosen, N., & Crews, C. M. (2021) · Nature Communications

Protein Degradation and InhibitorsMelanoma and MAPK Pathways

Cited by 152

Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor

Scaltriti, M., Chandarlapaty, S., Prudkin, L., Aura, C., Jimenez, J., Angelini, P. D., Sánchez, G., Guzman, M., Parra, J. L., Ellis, C., et al. (2010) · Clinical Cancer Research

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 151

Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

Yaeger, R., Mezzadra, R., Sinopoli, J., Bian, Y., Marasco, M., Kaplun, E., Gao, Y., Zhao, H., Paula, A. D. C., Zhu, Y., et al. (2023) · Cancer Discovery

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 144

BRAF — a tumour-agnostic drug target with lineage-specific dependencies

Hanrahan, A. J., Chen, Z., Rosen, N., & Solit, D. B. (2024) · Nature Reviews Clinical Oncology

Melanoma and MAPK PathwaysProtein Tyrosine Phosphatases

Cited by 136

Regulation of PTEN translation by PI3K signaling maintains pathway homeostasis

Mukherjee, R., Vanaja, K. G., Boyer, J. A., Gadal, S., Solomon, H., Chandarlapaty, S., Levchenko, A., & Rosen, N. (2021) · Molecular Cell

PI3K/AKT/mTOR signaling in cancerMetabolism, Diabetes, and Cancer

Cited by 135

Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma

Schatz, J. H., Oricchio, E., Wolfe, A. L., Jiang, M., Linkov, I., Maragulia, J., Shi, W., Zhang, Z., Rajasekhar, V. K., Pagano, N. C., et al. (2011) · Journal of Experimental Medicine

PI3K/AKT/mTOR signaling in cancerLymphoma Diagnosis and Treatment

Cited by 119

Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition

Yaeger, R., Yao, Z., Hyman, D. M., Hechtman, J. F., Vakiani, E., Zhao, H., Su, W., Wang, L., Joelson, A., Cercek, A., et al. (2017) · Cancer Research

Melanoma and MAPK PathwaysColorectal Cancer Treatments and Studies

Cited by 94

Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer

Kitai, H., Choi, P. H., Yang, Y. C., Boyer, J. A., Whaley, A., Pancholi, P., Thant, C., Reiter, J., Chen, K., Markov, V., et al. (2024) · Nature Communications

PI3K/AKT/mTOR signaling in cancerProtein Kinase Regulation and GTPase Signaling

Cited by 41

Supplementary Figure 4 from Molecular Characterization of Acquired Resistance to KRASG12C–EGFR Inhibition in Colorectal Cancer

Yaeger, R., Mezzadra, R., Sinopoli, J., Bian, Y., Marasco, M., Kaplun, E., Gao, Y., Zhao, H., Paula, A. D. C., Zhu, Y., et al. (2023)

Colorectal Cancer Treatments and StudiesLung Cancer Treatments and Mutations

Cited by 0